Outcomes After Endovascular or Open Repair for Degenerative Descending Thoracic Aortic Aneurysm Using Linked Hospital Data  by von Allmen, R.S. et al.
Abstracts
Gregory L. Moneta, MD, Section EditorStatin Use and Rupture of Abdominal Aortic Aneurysm
Wemmelund H, Høgh A, Hundborg HH, et al. Br J Surg 2014;101:966-75.
Conclusions: Statin use is associated with a reduced risk of rupture of
abdominal aortic aneurysm (AAA) and lower case fatality following rupture
of AAA.
Summary: There have been studies suggesting that statins may
reduce AAA growth rates and rupture risk by enhancing endothelial func-
tion and attenuating oxidative stress and inﬂammation of the vessel wall
(Liao JK. Am J Cardiol 2005;96: 24F-33F). Meta-analyses also suggests
decreased growth rate of AAAs with the use of statins (Sweeting MJ et al,
Br J Surg 2012;99:655-65). In addition there have been small, single-center
observational studies suggesting an association between prehospital statin
therapy and lower mortality following surgery for ruptured (rAAA) (Feeney
JM et al, J Am Coll Surg 2009;209:41-6). In the current study the authors
use the Danish National Registry of Patients, to examine incident rAAA
cases and AAA control patients with a focus on the risk and prognosis of
rAAA. This was a nationwide, population-based, combined case-control
and follow-up study that included all patients (aged at least 50 years) with
a ﬁrst-time hospital admission for rAAA and 1:1 matched AAA controls
without rupture in Denmark, from 1996 to 2008. Individual-level data
on preadmission drug use, co-morbidities, socioeconomic markers, health
care contacts and death were obtained from nationwide registries. The study
included 3584 cases and 3584 match controls. Current statin use was regis-
tered for 418 patients with rAAA (11.7%) and 539 AAA controls (15.0%),
corresponding to an age- and sex-matched odds ratio of 0.7 (95% conﬁ-
dence interval [CI], 0.60-0.81) for rAAA in current statin users vs never
users. The decreased risk of rAAA remained after adjustment for potential
confounding factors (adjusted odds ratio, 0.73; 95% CI, 0.61-0.86). Over-
all, 30-day mortality rate from time of hospital admission among patients
with rAAA was 46.1% in current statin users compared with 59.3% in never
users (adjusted mortality rate [MRR] 0.80; 95% CI, 0.68-0.95). Patients
who had formerly used statins did not have reduced mortality (adjusted
MRR, 0.98; 95% CI, 0.78-1.22).
Comment: The study suggests beneﬁts for statins in patients with
AAA both in lower rupture rates and improved survival of ruptures. How-
ever, it has a number of signiﬁcant limitations in that there was no data
on AAA diameter, a known predictor of rupture. It may also be possible
that patients who use statins are more cooperative in adherence to medical
recommendations and have greater contact with a health care system, and
therefore they are perhaps more healthy overall. Such patients may have
their aneurysms diagnosed at a smaller size prior to rupture where they
can be repaired electively. Nevertheless, given that patients with AAA gener-
ally have manifestations of atherosclerosis and vascular disease other than
AAA that beneﬁt from statins, there seems to be no downside to placing pa-
tients with AAAs on a statin medication. Certainly additional analyses of
possible mechanisms of beneﬁt are needed, but for the moment the results
of this study support current guidelines that recommend initiation of pro-
phylactic statin treatment in asymptomatic patients with AAA (Chaikof
EL et al, J Vasc Surg 2009;50(Suppl):S2-S49), and (Moll FL, Eur J Vasc
Endovasc Surg 2011;41(Suppl 1):S1-S58).
Outcomes After Endovascular or Open Repair for Degenerative
Descending Thoracic Aortic Aneurysm Using Linked Hospital Data
von Allmen RS, Anjum A, Powell JT. Br J Surg 2014;101:1244-51.
Conclusions: In England, mortality for treatment of degenerative
descending thoracic aneurysm is similar with open repair and TEVAR. Pa-
tients treated with TEVAR however higher re-intervention rates and worse
long-term survival.
Summary: Degenerative thoracic aortic aneurysms are now preferen-
tially treated with TEVAR instead of open repair by many surgeons. Com-
parisons however between TEVAR and open repair of degenerative thoracic
aortic aneurysms have generally been through the use of registries, and in
the U.S. a large Medicare database. The Medicare study determined 30-
day and 5-year survival for an elective and emergency repair of descendingthoracic aortic aneurysms between 1998 and 2007. Although mortality was
lower for TEVAR than open repair 6.1% vs 7.1%; this did not reach statis-
tical signiﬁcance. In addition, 5-year survival was worse after TEVAR
(73% vs 81%). This study however was conducted when TEVAR was under-
going fairly rapid technological change and to date updated reports were
not available (Goodney PP et al, Circulation 2011;124:2661-9). In this
study the authors analyzed patients aged over 50 years without a history
of aortic dissection, who underwent repair of a thoracic aortic aneurysm be-
tween 2006 and 2011, a more recent cohort than the Medicare study. Prin-
ciple outcomes were 30-day operative mortality, long-term survival
(5 years), and aortic-related reinterventions. TEVAR and open repair
were compared using mortality linked individual patient data from hospital
episodes statistics (England) with crude and multivariable models and
adjusted for age and sex. There were 759 patients who underwent thoracic
aortic aneurysm repair, mainly for intact aneurysms (n ¼ 618; 81.4%). Me-
dian ages of TEVAR and open cohorts were 73 and 71 years respectively (P
< .001). More men than women underwent TEVAR (P ¼ .004). For intact
aneurysms operative mortality rate was similar for TEVAR and open repair
(6.5% vs 7.6%; odds ratio, 0.79; 95% CI, 0.41-1.49). 5-year survival rate
however was signiﬁcantly worse after TEVAR (54.2% vs 65.6%; adjusted
hazard ratio [HR], 1.45; 95% CI, 1.08-1.94). After 5 years, aortic-related
mortality was similar in the two groups, but cardiopulmonary mortality
was higher after TEVAR. TEVAR was associated with more aortic-related
re-interventions (23.1% vs 14.3%; adjusted HR, 1.70, 95% CI, 1.11-
2.60). There were 141 procedures for ruptured thoracic aneurysm (97
TEVAR, 44 open) with TEVAR showing no signiﬁcant advantage in terms
of operative mortality.
Comment: It is certainly possible that selection bias and increased car-
diopulmonary morbidity may contribute to the decreased long-term survival
of patients treated with TEVAR vs open repair for thoracic aortic aneurysm.
Anecdotally, many surgeons feel patients with thoracic aneurysms have
increased comorbidities vs those with abdominal aortic aneurysms and
therefore ﬁnd TEVAR an attractive alternative to open repair reﬂected in
the increasing numbers of thoracic aneurysms treated with endovascular
techniques. However, we still don’t know whether the technique is cost-
effective and truly effective. Clearly TVAR can be costly, especially if one
considers the increase expense of surveillance and aortic related reinterven-
tions. The authors contend that based on the available data and lack of cost-
effectiveness data a shift to elective endovascular treatment of descending
thoracic aortic aneurysms is not justiﬁed.
A Randomized Trial Comparing Treatments for Varicose Veins
Brittenden J, Cotton SC, Elders A, et al. N Engl J Med 2014;371:1218-27.
Conclusions: In a comparison of ultrasound-guided foam sclerother-
apy, endovenous laser ablation and surgical treatment for treatment of vari-
cose veins, all treatments had similar clinical efﬁcacy. Complications were
less frequent after laser treatment and ablation rates lower after foam
treatment.
Summary: Endovenous thermal ablation techniques and ultrasound
guided foam sclerotherapy are widely employed alternatives to surgery
for the treatment of varicose veins. Smaller randomized trials and meta-an-
alyses have concluded these treatments can be effective in terms of short-
term technical success in clinician reported outcomes. However, despite
the fact clinical practice guidelines recommend use of patient reported
quality of life to assess outcomes of procedures for varicose veins, quality
of life has never been the primary outcome measure in any randomized tri-
als involving treatment foam sclerotherapy. The authors therefore per-
formed a comparison of laser, surgery and foam sclerotherapy (CLASS)
trial to assess the relative efﬁcacies of these treatments in patients with pri-
mary varicose veins. This was a randomized trial involving 798 participants
with primary varicose veins at 11 centers in the United Kingdom. Out-
comes of foam, laser and surgical treatments were compared at 6 months
with disease-speciﬁc quality of life and generic quality of life questionnaires
as measured on several scales. Secondary outcomes included complications
and measures of clinical success. After adjustment for baseline scores and1709
